Mr. Platteeuw holds a master’s degree in Chemistry from the University of Nijmegen, The Netherlands. He started his career at Synthon BV as Project Manager of pharmaceutical product development and later became the company’s Head of Galenical R&D. In this latter position, Mr. Platteeuw contributed to the development of Synthon’s R&D organization and product portfolio, including the granting of 10 worldwide patents. In 2004 he moved to Dafra Pharma, a private company specialized in antimalarial medication where he acted as Director R&D and was instrumental for the launch of Co-Arinate which provided an effective treatment of malaria within 24 hours and which ever since has been the top selling product of Dafra. In 2005, he started Avivia BV, an independent company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products. Through Avivia he has been hired by many companies in roles as project manager (Disphar, Organon/SP, Pharming, Virostatics, Genetic Immunity, Metaptys), chief operating officer (Formac Pharmaceuticals), chief development officer (Chamaeleo) or director pharmaceutical R&D (Pantarhei). For most of these companies his work resulted in further patent applications (15), licensing deals and significant market revenue.  

  Pharmaceuticals, Genetic Immunity, Metaptys